SILVER SPRING
High-dose Spinraza regimen approved for spinal muscular atrophy
- Sponsor
- Biogen Inc. $BIIB
- Drug
- Spinraza · nusinersen
- Indication
- spinal muscular atrophy
FDA approved a high-dose regimen of Spinraza (nusinersen) for spinal muscular atrophy.
What this means
Spinraza is an injected drug that helps treat spinal muscular atrophy by boosting a protein needed for muscle movement. The FDA just approved a higher-dose version of Spinraza for patients with this rare nerve-muscle disease. This could give doctors more flexibility in dosing for patients who may need stronger treatment to manage their symptoms.
Drug Watch — recent news on Spinraza
- HSE finally approves Spinraza for the treatment of children with spinal muscular atrophy (SNA) - rollercoaster.ie
- US approves world’s first drug to treat muscle atrophy in SMA - Новости GxP
- Scholar Rock gets first drug approval as FDA okays Isembyld - pharmaphorum
- FDA OKs Isembyld as first muscle-strengthening therapy for SMA - SMA News Today
- SMC Extends SMA Drug Access to Newborns - medscape.com
Sponsor Watch — recent news on Biogen Inc.
- Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
- Is Biogen Stock Outperforming the S&P 500?
- How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
- Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?